Perfusion Bioreactor With AI Control Market Report 2026

The perfusion bioreactor with artificial intelligence (ai) control market size has grown exponentially in recent years. It will grow from $1.88 billion in 2025 to $2.28 billion in 2026 at a compound annual growth rate (CAGR) of 21.1%. The growth in the historic period can be attributed to increasing biologics manufacturing demand, expansion of monoclonal antibody production, rising adoption of perfusion-based cell culture, improvements in sensor and automation technologies, growing use of single-use bioprocessing systems.

The perfusion bioreactor with artificial intelligence (ai) control market size is expected to see exponential growth in the next few years. It will grow to $4.85 billion in 2030 at a compound annual growth rate (CAGR) of 20.8%. The growth in the forecast period can be attributed to increasing investments in ai-enabled biomanufacturing, rising demand for cell and gene therapies, expansion of continuous manufacturing adoption, growing focus on process scalability and efficiency, increased regulatory acceptance of advanced bioprocess technologies. Major trends in the forecast period include increasing adoption of ai-driven perfusion control systems, rising use of continuous cell culture platforms, growing demand for single-use perfusion bioreactors, expansion of real-time process optimization capabilities, enhanced focus on yield and process consistency.

The rising adoption of personalized medicine is expected to drive the growth of the perfusion bioreactor with artificial intelligence (AI) control market in the coming years. Personalized medicine involves tailoring medical treatment to an individual’s genetic, molecular, and clinical characteristics for more accurate and effective care. Its adoption is growing due to advancements in genomics, which enable therapies customized to a patient’s unique genetic profile for improved efficacy and safety. Perfusion bioreactors with AI control facilitate personalized medicine by allowing precise, continuous production of patient-specific cells, such as stem cells or engineered tissues, under tightly regulated conditions. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022. The newly approved treatments in 2023 also included seven cancer drugs and three for other diseases and conditions. Consequently, the growing adoption of personalized medicine is boosting the expansion of the perfusion bioreactor with AI control market.

Major companies operating in the perfusion bioreactor with artificial intelligence (AI) control market are concentrating on developing advanced strategies, such as AI-enhanced real-time bioprocess monitoring, to optimize cell culture performance, increase product yield, and lower operational costs in biopharmaceutical manufacturing. AI-enhanced real-time bioprocess monitoring involves the use of artificial intelligence algorithms to continuously evaluate bioreactor data, providing real-time insights, predictive adjustments, and optimization of cell growth and product quality during biomanufacturing. For example, in February 2025, The Cultivated B GmbH, a Germany-based biotechnology company, introduced AI-driven multi-channel biosensors aimed at improving real-time monitoring of bioreactors in cell culture and fermentation processes. These biosensors deliver continuous high-resolution data analytics, allowing bioprocess engineers to track growth and metabolism with exceptional sensitivity, detecting molecules at sub-picomolar levels such as glucose, amino acids, and lactic acid. The AI integration provides real-time insights and recommendations to optimize media formulation, enhance measurement reliability, minimize contamination risk by eliminating manual sampling, and accelerate product development for applications in pharmaceuticals, biologics, food biotechnology, waste upcycling, and alternative protein production.

In August 2025, Culture Biosciences Inc., a US-based biotechnology company, formed a partnership with Cytiva Bioscience Holding Ltd. to advance digital bioprocessing solutions. The collaboration aims to accelerate and reduce risks in upstream bioprocess development by providing scalable, cloud-connected, and digitally integrated bioreactor systems that enable faster and more predictable therapeutic production from benchtop to commercial scale. Cytiva Bioscience Holding Ltd. is a US-based biotechnology company offering a perfusion bioreactor with artificial intelligence (AI) control.

Major companies operating in the perfusion bioreactor with artificial intelligence (ai) control market are Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group AG., Danaher Corporation, Sartorius Aktiengesellschaft, Getinge AB., WuXi Biologics Inc., Eppendorf Aktiengesellschaft, ABEC Inc., Catalyx.ai, PBS Biotech Inc., Cytovance Biologics, Culture Biosciences Inc., Esco Lifesciences Group Ltd., Cell Culture Company GmbH, Synthecon Inc., OmniBRx Biotechnologies Inc., ProlifeCell Inc., Sciperio Ltd., The Cultivated B Ltd.

North America was the largest region in the perfusion bioreactor with artificial intelligence (AI) control market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the perfusion bioreactor with artificial intelligence (ai) control market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the perfusion bioreactor with artificial intelligence (ai) control market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the perfusion bioreactor with AI control market by increasing costs of imported sensors, control software modules, precision pumps, filtration components, and stainless steel or single-use assemblies used in advanced bioreactor systems. Biopharmaceutical manufacturing hubs in North America and Europe are most affected due to reliance on imported automation hardware and electronic components, while Asia-Pacific faces higher costs for AI-enabled bioprocess equipment imports. These tariffs are increasing capital expenditure and lengthening system deployment timelines. However, they are also encouraging domestic manufacturing of bioreactor components, localized AI software development, and regional supplier partnerships that strengthen long-term supply chain resilience.

The perfusion bioreactor with artificial intelligence (ai) control market research report is one of a series of new reports that provides perfusion bioreactor with artificial intelligence (ai) control market statistics, including perfusion bioreactor with artificial intelligence (ai) control industry global market size, regional shares, competitors with a perfusion bioreactor with artificial intelligence (ai) control market share, detailed perfusion bioreactor with artificial intelligence (ai) control market segments, market trends and opportunities, and any further data you may need to thrive in the perfusion bioreactor with artificial intelligence (ai) control industry. This perfusion bioreactor with artificial intelligence (ai) control market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A perfusion bioreactor with artificial intelligence (AI) control is a bioreactor system designed for continuous cell culture that delivers fresh media and eliminates waste. AI tracks critical parameters and automatically adjusts conditions to enhance productivity, consistency, and efficiency in the production of biologics or cell-based products.

The main product types of perfusion bioreactors with artificial intelligence (AI) control include single-use perfusion bioreactors and multi-use perfusion bioreactors. Single-use perfusion bioreactors are disposable systems designed for continuous cell culture, improving scalability and minimizing contamination in biomanufacturing. Artificial intelligence (AI) control capabilities include predictive analytics, process optimization, real-time monitoring, automated feedback control, and more. These bioreactors are utilized in cell therapy, monoclonal antibody production, vaccine manufacturing, stem cell research, and other applications, catering to end-users such as biopharmaceutical companies, academic and research institutes, contract manufacturing organizations, and others.

The perfusion bioreactor with artificial intelligence (AI) control market consists of revenues earned by entities by providing services such as cell culture management, nutrient and waste regulation, AI-driven process control, performance optimization, and automated data analytics. The market value includes the value of related goods sold by the service provider or included within the service offering. The perfusion bioreactor with artificial intelligence (AI) control market includes sales of automated perfusion bioreactor systems, hybrid perfusion bioreactors, and AI-integrated bench-scale perfusion bioreactors. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.